Captopril

• Catalog No.: Bio-0622
• CAS Number: 62571-86-2
• M. F.: C9H15NO3S
• M. W.: 217.2853

SYNONYMS

• IUPAC name: (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
• IUPAC Traditional name: (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
• Synonyms: Capoten; Capace; Acenorm; Acepril

DATABASE IDS

• CAS Number: 62571-86-2

PROPERTIES

• Application(s): Exp. drug for treatment of myocardial infarction
• Application(s): Smooth muscle relaxant
• Description: Diastereomers
• Application(s): Antihypertensive agent
• Application(s): Drug used for diagnosis and treatment of renin-dependent hypertension
• Mechanism of Action: ACE inhibitor
• Mechanism of Action: May inhibit local angiotensin 2 at vascular and renal sites so attenuating catecholamine release
• Mechanism of Action: May increase prostaglandin synthesis
• Mechanism of Action: Increases urinary excretion of PGE2
• Mechanism of Action: increases plasma-renin activity resulting from loss of negative feedback on renin release due to reduced angiotensin-2 concentration
• Mechanism of Action: increases plasma levels of PGE2 and PGE2-alpha metabolites.
• Mechanism of Action: increased sodium-excretion
• Mechanism of Action: increased plasma-renin causes decrease in aldosterone-secretion resulting in: small increases in serum-potassium
• Mechanism of Action: decreases plasma-angiotensin-2 concentration
• Mechanism of Action: decrease in plasma-volume
• Mechanism of Action: apparent primary action involves suppression of the renin-angiotensin-aldosterone-system
• Mechanism of Action: angiotensin-antagonist

REFERENCES

• Ger. Pat., 1977, Squibb, 2 703 828; CA, 88, 7376c, (synth)
• Ondetti, M.A. et al., Science (Washington, D.C.), 1977, 196, 441, (use)
• Cardoni, A.A. et al., Drug Intell. Clin. Pharm., 1981, 15, 932, (pharmacol, rev)
• Horovitz, Z.P. et al., Pharmacol. Biochem. Prop. Drug Subst., 1981, 3, 148, (pharmacol)
• Kadin, H., Anal. Profiles Drug Subst., 1982, 11, 79, (synth, prop, detn, pharmacol, rev)
• Shimazaki, M. et al., Chem. Pharm. Bull., 1982, 30, 3139, (synth)
• Condon, M.E. et al., J. Med. Chem., 1982, 25, 250, (synth)
• Migdalof, B.H. et al., Drug Metab. Rev., 1984, 15, 841, (rev)
• Aboul-Enein, H.Y. et al., Spectrosc. Lett., 1985, 18, 419, (pmr, conformn)
• Drummer, O.H. et al., Med. Res. Rev., 1986, 6, 75, (rev, metab)
• Negwer, M., Organic-Chemical Drugs and their Synonyms, 6th edn., Akademie-Verlag, 1987, 1331
• Bashiardes, C. et al., Tet. Lett., 1987, 28, 5563, (synth)
• ACE Inhibitors: Current Use and Future Prospects, (ed. Schachter, M.), Martin Dunitz, London, 1995, (book)
• Martindale, The Extra Pharmacopoeia, 32nd edn., Pharmaceutical Press, 1999, 836
• Lewis, R.J., Sax's Dangerous Properties of Industrial Materials, 8th edn., Van Nostrand Reinhold, 1992, MCO750